Molecular Biology in Medicinal Chemistry

by ; ; ; ;
Edition: 1st
Format: Hardcover
Pub. Date: 2004-02-13
Publisher(s): Wiley-VCH
List Price: $275.37

Buy New

Usually Ships in 8 - 10 Business Days.
$262.26

Rent Textbook

Select for Price
There was a problem. Please try again later.

Used Textbook

We're Sorry
Sold Out

eTextbook

We're Sorry
Not Available

How Marketplace Works:

  • This item is offered by an independent seller and not shipped from our warehouse
  • Item details like edition and cover design may differ from our description; see seller's comments before ordering.
  • Sellers much confirm and ship within two business days; otherwise, the order will be cancelled and refunded.
  • Marketplace purchases cannot be returned to eCampus.com. Contact the seller directly for inquiries; if no response within two days, contact customer service.
  • Additional shipping costs apply to Marketplace purchases. Review shipping costs at checkout.

Summary

This readily comprehensible book explains the identification of molecular targets via cellular assays, reporter genes or transgenic models, as well as surveying recent advances in the synthesis, separation and analysis of drugs. A special section is devoted to molecular genetics methods.With its examination of these novel methods and generous practical advice, this is essential reading for all pharmaceutical chemists, molecular biologists and medical researchers using molecular methods to study drugs and their action.

Author Biography

<b>Theodor Dingermann</b>, born 1948, studied pharmacy at the University of Erlangen, Germany. After obtaining his PhD in biochemistry, he worked as a post-doc at Yale University, New Haven. In 1987 he completed his habilitation for the disciplines of biochemistry and molecular biology. Since 1990 he is full professor of pharmaceutical chemistry at the Goethe University in Frankfurt (Germany). He is editor-in-chief of two journals, &#8220;DIE PHARMAZIE&#8221; and &#8220;Pharmazie in unserer Zeit&#8221;. Furthermore, he is chairman of the working group on biopharmaceuticals and vice-chairman of the committee on pharmaceutical biology of the German Arzeibuch commission. From 2000 to 2004 he has been president of the German Pharmaceutical Society. <p> <b>Dieter Steinhilber</b>, born 1959, studied pharmacy at the University of T&#252;bingen (Germany). After an assistantship there he spent a postdoc period with Nobel prize winner Bengt Samuelson in Stockholm (Sweden). In 1994 he received an associate professorship and since 2000 he is a full professor for pharmaceutical chemistry at the Goethe University in Frankfurt (Germany). Since 1999 he is also director of the Institute of Pharmaceutical Chemistry. From 1999 to 2000 he was dean of the Faculty for Biochemistry, Pharmacy and Food Chemistry. Prof. Steinhilber is the chairman of a European graduate school funded by the German Research Foundation (DFG) and is the chairman of the scientific board of Phenion, a company for molecular cell physiology. <p> <b>Gerd Folkerss</b> is professor of pharmaceutical chemistry at the ETH-Z&#252;rich since 1991. He studied pharmacy at the University of Bonn and earned his Ph.D. on structure activity relationships of desapunines. He then moved to the University of T&#252;bingen, where he completed his habilitation in pharmaceutical chemistry. During a stay with H.-D. Hoeltje in Bern, he studied new research methods at the Birkbeck College and E. Meyer at Texas A&amp;M University.<br> The focus of his research is the molecular interaction between drugs and their binding sites. Besides his work on the molecular mechanism of &#8220;conventional&#8221; nucleoside therapeutics against virus infection and cancer, his special interest has shifted to immuno-therapeutics.

Table of Contents

Preface.
Foreword.
Contributors.
PART I: MOLECULAR TARGETS.
1. Cellular Assays in Drug Discovery (H. Albrecht, et al.).
2. Gene Knockout Models (P. Ruth & M. Sausbier).
3. Reporter Gene Assay Systems for the Investigation of G-protein-coupled Receptors (M. Dinger & A. Beck-Sickinger).
4. From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors (R. Bakker & R. Leurs).
PART II: SYNTHESIS.
5. Stereoselective Synthesis with the Help of Recombinant Enzymes  (N. Rao & A. Liese).
6. Nucleic Acid Drugs (J. Engels & J. Parsch).
PART III: ANALYSIS.
7. Recent Trends in Enantioseparation of Chiral Drugs (B. Chankvetadze).
8. Affinity Chromatography (G. Scriba).
9. Nuclear Magnetic Resonance-based Drug Discovery (U. Günther, et al.).
10.13C- and 15N-Isotopic Labeling of Proteins (C. Klammt, et al.).
11. Application of Antibody Fragments as Crystallization Enhancers (C. Hunte & C. Münke).
PART IV: KINETICS, METABOLISM AND TOXICOLOGY.
12. Pharmacogenetics: The Effect of Inherited Genetic Variation on Drug Disposition and Drug Response (K. Kesseler).
13. Pharmacogenomics of Bioavaliability and Elimination (I Cascorbi & H. Kroemer).
14. Toxicogenomics: Integration of New Molecular Biological Tools in Toxicology (W. Heijne, et al.).
Index.

An electronic version of this book is available through VitalSource.

This book is viewable on PC, Mac, iPhone, iPad, iPod Touch, and most smartphones.

By purchasing, you will be able to view this book online, as well as download it, for the chosen number of days.

Digital License

You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.

More details can be found here.

A downloadable version of this book is available through the eCampus Reader or compatible Adobe readers.

Applications are available on iOS, Android, PC, Mac, and Windows Mobile platforms.

Please view the compatibility matrix prior to purchase.